Jun 2026 (Q2 FY26) — Jul 28, 2026
IQVIA Q2 FY26 — Strong Operational Performance and Raised Full-Year Guidance
Read the full callIQVIA (IQV) earnings
- Mar 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
IQVIA earnings: last reported Tue, 28 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 4,151 | +8.4% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 12.4 | −0.6 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 274 | +10.0% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
37 of 39 judged targets kept · 23 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Second-quarter adjusted diluted EPS | $2.98 to $3.08 | Mar 2026 | Second quarter adjusted diluted EPS of $3.15 also exceeded the high end of our guidance range and increased 12.1% year-over-year. | Achieved |
| Full-year adjusted diluted EPS | $12.55 to $12.85 | Dec 2025 | we are also raising adjusted diluted EPS to be between $12.80 and $13, up 7.4% to 9.1% versus prior year or 8.2% at the midpoint | Revised Up |
| Full-year adjusted EBITDA margin | flat year-over-year | Dec 2025 | reconfirming flat margins year-over-year at approximately 23.2% | On Track |
2 of IQVIA HOLDINGS INC.'s 62 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 59 more targets are in the full ledger.
Claimed
- Q2 revenue exceeded the high end of guidance, growing 8.7% reported and 8.5% constant currency.
- Q2 adjusted diluted EPS of $3.15 exceeded the high end of guidance, increasing 12.1% year-over-year.
- Organic growth accelerated to 6% year-over-year, three times the rate delivered a year ago.
- R&D Solutions net new bookings reached $3.15 billion, representing 19% growth year-over-year, with a 1.22 book-to-bill ratio.
- Last 12 months net new bookings were $11.3 billion as of June 30, up 13% year-over-year.
Qualified
Price
$265.88 −0.38% · −$1.02
Performance +30.0% 1Y
1Y: $204.55 on 17 Oct 2025 → $265.88. High $275.02 (24 Sept 2026), low $156.66 (29 Apr 2026).
- Previous close
- $266.9
- 52-week range
- $156.66 – $275.02
- One year
- +25.39%
Overview
- Symbol
- IQV
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
37 of 39 judged targets kept · 23 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Second-quarter adjusted diluted EPS | $2.98 to $3.08 | Mar 2026 | Second quarter adjusted diluted EPS of $3.15 also exceeded the high end of our guidance range and increased 12.1% year-over-year. | Achieved |
| Full-year adjusted diluted EPS | $12.55 to $12.85 | Dec 2025 | we are also raising adjusted diluted EPS to be between $12.80 and $13, up 7.4% to 9.1% versus prior year or 8.2% at the midpoint | Revised Up |
| Full-year adjusted EBITDA margin | flat year-over-year | Dec 2025 | reconfirming flat margins year-over-year at approximately 23.2% | On Track |
Claimed
- Q2 revenue exceeded the high end of guidance, growing 8.7% reported and 8.5% constant currency.
- Q2 adjusted diluted EPS of $3.15 exceeded the high end of guidance, increasing 12.1% year-over-year.
- Organic growth accelerated to 6% year-over-year, three times the rate delivered a year ago.
- R&D Solutions net new bookings reached $3.15 billion, representing 19% growth year-over-year, with a 1.22 book-to-bill ratio.
- Last 12 months net new bookings were $11.3 billion as of June 30, up 13% year-over-year.
Qualified
The full ledger
Open IQVIA HOLDINGS INC.’s full ledger
A free account opens 5 company ledgers a month. All 62 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
IQVIA Q1 FY26 — Strong Organic Growth and AI Adoption Drive Record Performance
Read the full callDec 2025 (Q4 FY25) — Feb 5, 2026
IQVIA Holdings Q4 FY25 — Strong Finish to the Year with Robust Bookings and AI Momentum
Read the full callEvery analysed call
IQVIA earnings calls (IQV)
Financials
What the filings say
Net profit, year on year: +10% (quarter to mar 2026 against mar 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,814 | 3,896 | 3,958 | 3,829 | 4,017 | 4,100 | 4,364 | 4,151 |
| Operating profit | 520 | 550 | 626 | 496 | 506 | 553 | 627 | 514 |
| Operating margin | 13.6% | 14.1% | 15.8% | 12.9% | 12.6% | 13.5% | 14.4% | 12.4% |
| Interest | 163 | 170 | 171 | 165 | 182 | 189 | 193 | 192 |
| Profit before tax | 436 | 349 | 544 | 323 | 323 | 408 | 537 | 328 |
| Tax rate | 17.2% | 18.6% | 20.6% | 18.9% | 17.3% | 18.6% | 11.0% | 18.0% |
| Net profit | 363 | 285 | 437 | 249 | 266 | 331 | 514 | 274 |
| EPS ($ per share) | 1.99 | 1.57 | — | 1.42 | 1.55 | 1.94 | — | 1.63 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 10,901 | 11,049 | 11,095 | 10,777 | 10,898 | 11,028 | 11,143 | 11,378 |
| Reserves | 807 | 998 | 1,277 | 2,243 | 3,334 | 4,692 | 6,065 | 7,425 |
| Total liabilities | 15,595 | 16,988 | 18,284 | 18,647 | 19,572 | 20,569 | 20,832 | 23,314 |
| Fixed assets | 434 | 458 | 482 | 497 | 532 | 523 | 535 | 533 |
| Investments | 47 | 62 | 88 | 111 | 93 | 120 | 141 | 161 |
| Total assets | 22,549 | 23,251 | 24,564 | 24,689 | 25,337 | 26,681 | 26,899 | 29,944 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,254 | 1,417 | 1,959 | 2,942 | 2,260 | 2,149 | 2,716 | 2,654 |
| Cash from investing | -810 | -1,190 | -796 | -2,103 | -2,006 | -1,603 | -1,444 | -2,305 |
| Cash from financing | -452 | -276 | -217 | -1,235 | -329 | -382 | -878 | -150 |
| Net cash flow | -68 | -54 | 977 | -448 | -150 | 160 | 326 | 278 |
| Capital expenditure | -459 | -582 | -616 | -640 | -674 | -649 | -602 | -603 |
| Free cash flow | 795 | 835 | 1,343 | 2,302 | 1,586 | 1,500 | 2,114 | 2,051 |
IQV revenue by segment
Research and Development Solutions grew from 55% to 59% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Research and Development Solutions | 55% | 54% | 55% | 55% | 55% | 53% | 58% | 59% | +17.0% |
| Commercial Solutions | — | — | — | — | — | — | 42% | 41% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
IQV operating KPIs by quarter
| KPI | Mar 2025 Q1 FY25 | Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|---|
| Backlog R&D Solutions | $31.5BR&DS backlog at March 31 was $31.5 billion, an increase of 4.8% year-over-year and 4.6% at constant currency.Source: earnings call transcript | $32.1BR&DS backlog at June 30 was $32.1 billion, an increase of 5.1% year-over-year.Source: earnings call transcript | $32.4BFinally, our backlog reached a new record of $32.4 billion at the end of the quarter showing growth of 4.1% compared to the prior year.Source: earnings call transcript | $32.7BBacklog reached a new record of $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year.Source: earnings call transcript | $34.2BRDS backlog at March 31 was $34.2 billion, which is an increase of mid-single digit year-over-year.Source: earnings call transcript | $34.2BAs of June 30, R&DS backlog was $34.2 billion and the next 12-month revenue from this backlog was $9.230 billion which is up 7.5% versus last year.Source: earnings call transcript | 0% |
| Book-to-bill ratio | — | — | — | — | 1.04 ratioWhile our book-to-bill ratio 1.04 in the quarter despite solid service fee bookings growth and normal cancellations.Source: earnings call transcript | 1.22 ratioIf I may add, this 1.22 was in a quarter where our revenue was up almost 9% year-over-year, stronger than anticipated.Source: earnings call transcript | +17.3% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- Americas 47% ↓ 0 pt
- EMEA 32% ↓ 1 pt
- Asia Pacific 21% ↑ 1 pt
As IQV cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
56 filings between Oct 29, 2025 and Sep 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$51.36M
17 sales by 6 insiders
Compensation
not trading decisions- 14
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
- 14
- Tax withheld — shares kept back by the company to cover tax
Also filed: 6 dispositions to the issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BOUSBIB ARI | — | $46.69M | Jul 29, 2026 |
| Sherbet Eric | — | $2.12M | Jul 29, 2026 |
| STAUB W RICHARD | — | $1.28M | Aug 3, 2026 |
| Berkshire James G. | — | $697.2K | Sep 2, 2026 |
| Patel Bhavik | — | $436.4K | Jul 31, 2026 |
| Cherofsky Keriann | — | $136.8K | Jul 29, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Berkshire James G. See Remarks | Sale | 2,668 | $697.2K |
| Sep 2, 2026 | Berkshire James G. See Remarks | Option exercise | 5,381 | $709.3K |
| Sep 2, 2026 | Berkshire James G. See Remarks | Disposition to issuer | 2,713 | $709.6K |
| Aug 3, 2026 | STAUB W RICHARD See Remarks | Sale | 5,500 | $1.28M |
| Jul 31, 2026 | Patel Bhavik See Remarks | Sale | 1,855 | $436.4K |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Option exercise | 156,206 | $12.22M |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Sale | 4,465 | $1.10M |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Sale | 4,584 | $1.13M |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Sale | 44,039 | $10.84M |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Sale | 53,191 | $13.02M |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Disposition to issuer | 47,858 | $11.71M |
| Jul 29, 2026 | BOUSBIB ARI See Remarks | Disposition to issuer | 2,069 | $511.0K |
| Jul 29, 2026 | Cherofsky Keriann See Remarks | Sale | 558 | $136.8K |
| Jul 29, 2026 | Sherbet Eric See Remarks | Sale | 5,000 | $1.25M |
| Apr 23, 2026 | DANHAKL JOHN G Director | Award | 1,571 | $0 |
| Apr 23, 2026 | GOGGINS COLLEEN A Director | Award | 1,571 | $0 |
| Apr 23, 2026 | LEONARD JOHN M Director | Award | 1,571 | $0 |
| Apr 23, 2026 | Burt Carol Director | Award | 1,571 | $0 |
| Feb 13, 2026 | Fedock Michael J. See Remarks | Tax withheld | 123 | $20.5K |
| Feb 13, 2026 | Haas Bernd See Remarks | Tax withheld | 20 | $3.3K |
| Feb 8, 2026 | Grenfell Alistair See Remarks | Award | 11,795 | $0 |
| Feb 8, 2026 | BOUSBIB ARI See Remarks | Award | 57,177 | $0 |
| Feb 8, 2026 | BOUSBIB ARI See Remarks | Tax withheld | 28,399 | $5.32M |
| Feb 8, 2026 | Berkshire James G. See Remarks | Award | 2,722 | $0 |
| Feb 8, 2026 | Berkshire James G. See Remarks | Tax withheld | 1,280 | $240.0K |
| Feb 8, 2026 | Bruehlman Ronald E See Remarks | Award | 16,335 | $0 |
| Feb 8, 2026 | Bruehlman Ronald E See Remarks | Tax withheld | 6,801 | $1.28M |
| Feb 8, 2026 | Cherofsky Keriann See Remarks | Award | 1,087 | $0 |
| Feb 8, 2026 | Cherofsky Keriann See Remarks | Tax withheld | 415 | $77.8K |
| Feb 8, 2026 | STAUB W RICHARD See Remarks | Award | 2,722 | $0 |
| Feb 8, 2026 | STAUB W RICHARD See Remarks | Tax withheld | 806 | $151.1K |
| Feb 8, 2026 | Sherbet Eric See Remarks | Award | 6,806 | $0 |
| Feb 8, 2026 | Sherbet Eric See Remarks | Tax withheld | 1,915 | $359.0K |
| Feb 8, 2026 | Patel Bhavik See Remarks | Award | 4,083 | $0 |
| Feb 8, 2026 | Patel Bhavik See Remarks | Tax withheld | 1,920 | $360.0K |
| Feb 8, 2026 | Fedock Michael J. See Remarks | Award | 6,735 | $0 |
| Feb 8, 2026 | Fedock Michael J. See Remarks | Tax withheld | 2,420 | $453.7K |
| Feb 8, 2026 | Grenfell Alistair See Remarks | Tax withheld | 5,545 | $1.04M |
| Feb 8, 2026 | Haas Bernd See Remarks | Award | 8,265 | $0 |
| Feb 8, 2026 | Haas Bernd See Remarks | Tax withheld | 440 | $82.5K |
| Feb 7, 2026 | Fedock Michael J. See Remarks | Tax withheld | 111 | $20.8K |
| Jan 28, 2026 | Fedock Michael J. See Remarks | Tax withheld | 381 | $91.3K |
| Dec 18, 2025 | BOUSBIB ARI See Remarks | Sale | 36,564 | $8.13M |
| Dec 18, 2025 | BOUSBIB ARI See Remarks | Disposition to issuer | 13,436 | $3.00M |
| Dec 18, 2025 | BOUSBIB ARI See Remarks | Option exercise | 50,000 | $3.00M |
| Oct 29, 2025 | BOUSBIB ARI See Remarks | Sale | 800 | $174.1K |
| Oct 29, 2025 | BOUSBIB ARI See Remarks | Option exercise | 77,592 | $4.65M |
| Oct 29, 2025 | BOUSBIB ARI See Remarks | Sale | 7,315 | $1.60M |
| Oct 29, 2025 | BOUSBIB ARI See Remarks | Sale | 13,741 | $3.01M |
| Oct 29, 2025 | BOUSBIB ARI See Remarks | Sale | 4,600 | $1.01M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for IQVIA HOLDINGS INC.
Free account. Everything above stays public.
Write why you follow IQVIA HOLDINGS INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading